PTN Palatin Technologies, Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.…
Industry Peers
BiotechnologyKey Statistics
About Palatin Technologies (NASDAQ: PTN)
›
Palatin Technologies (NASDAQ: PTN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 25 employees.
The shares were at 6.230 USD on 13 November 2026, down 38.7% over 52 weeks. Its 52-week range is 4.510 USD to 31.00 USD: the price is 79.9% below the high and 38.1% above the low.
Its market capitalisation is 11.10M USD.
Palatin Technologies reports return on equity of -125.3% and an operating margin of -65.7%.
It holds more cash than debt, a net cash position of 7.27M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.